ARST, PWRM, RPRX Mid- Day Stock Report !

LevelStock.com Newsletter

LevelStock.com Newsletter June 11th 2010.

ArcSight, Inc. (NASDAQ: ARST)

ArcSight Reports 41% Year-over-Year Quarterly Growth for Fiscal Fourth Quarter Ended April 30, 2010

ARST, a leading global provider of security and compliance management solutions that protect enterprises and government agencies, today announced financial results for its fiscal fourth quarter and fiscal year ended April 30, 2010.
 

For the fourth quarter of fiscal 2010, ArcSight reported total revenues of $55.2 million compared to total revenues of $39.3 million reported in the fourth quarter of fiscal 2009. Net income on a GAAP basis for the fourth quarter of fiscal 2010 was $22.6 million, or $0.62 per diluted share, including $222,000 in amortization of intangible assets, $3.0 million in stock-based compensation expense and an $18.6 million income tax benefit resulting from the release of the company's valuation allowance of its deferred tax assets. This compares to a GAAP net income of $4.3 million, or $0.13 per diluted share, reported in the fourth quarter of fiscal 2009, including $211,000 in amortization of intangible assets and $1.6 million in stock-based compensation expense.





Read More
http://finance.yahoo.com/news/ArcSight-Reports-41-bw-4077684351.html?x=0&.v=1



_____________________________________________________________________



Power3 Medical Products, Inc. (OTCBB: PWRM)

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro(TM), a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro(R), a serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS diseases, currently engaged in Phase II clinical trials. These products are designed to analyze proteins and their mutations to assess an individual's risk for developing disease later in life, a patient's likelihood of responding to a particular drug, a patient's risk of disease progression and disease recurrence, to measure a patient's exposure to drug therapy, to ensure optimal dosing and reduced drug toxicity.

For more information
http://www.power3medical.com.

_____________________________________________________________________

(NasdaqCM:RPRX)

 

FDA Lifts Full Clinical Hold on Repros' Proellex®

RPRX today announced it has received written confirmation from the FDA noting the full clinical hold on Proellex(R) has been lifted. The Company will be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both safety and signals of efficacy in an escalating dose fashion.


The new study will test 5 different doses of Proellex (1, 3, 6, 9 and 12 mg) with 1 mg being the first dose tested. Each dose will be compared to placebo with weekly assessments of liver function during both the placebo and drug period. Higher doses will not be studied until the Company is confident that it is safe to proceed to the next dose and has reported the safety findings to the FDA. Subjects will be dosed with the active drug for 10 weeks, which will allow for adequate time to determine the impact of a given dose on trends in liver function. Each dose will be tested in 12 different subjects and assessment of pharmacokinetic parameters will be obtained at start of dosing and end of the dosing period to determine overall and maximum drug exposure for a given dose. The Company will also monitor changes in menstrual bleeding patterns and ovulation as well as changes in endometrial thickness. The FDA requires that an independent Drug Safety Monitoring Board be established and that the "Informed Consent" clearly state the liver toxicity previously experienced with Proellex. The Company believes the toxicity experienced was dose dependent and that the lower doses being tested now are outside the range where toxicity was previously seen.





Read More
http://finance.yahoo.com/news/FDA-Lifts-Full-Clinical-Hold-bw-4167413943.html?x=0&.v=1

_______________________________________________________________________________

  Stay Tuned. Happy Trading !

LevelStock.com